Notably, JAK-STAT hyperactivation drives the inflammatory cascade in atopic dermatitis (AD), positioning JAK inhibitors (e.g., tofacitinib, baricitinib) as first-line therapeutic agents for moderate-to-severe AD [3, 4]. The gene discussed is SOAT1; the disease is Alzheimer disease.